Get the Stockscreener App
3.5055
1.82%
-0.0645
Annexon Inc stock is traded at $3.5055, with a volume of 426.46K.
It is down -1.82% in the last 24 hours and down -30.59% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$3.57
Open:
$3.57
24h Volume:
426.46K
Relative Volume:
0.30
Market Cap:
$380.54M
Revenue:
-
Net Income/Loss:
$-134.24M
P/E Ratio:
-1.9805
EPS:
-1.77
Net Cash Flow:
$-121.34M
1W Performance:
-8.72%
1M Performance:
-30.59%
6M Performance:
-34.97%
1Y Performance:
-37.30%
1-Day Range:
$3.475
$3.60
1-Week Range:
$3.435
$3.82
52-Week Range:
$3.435
$8.40
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650)-822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
3.505 | 380.54M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.30 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.62 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.97 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.75 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon Inc (ANNX) Shares Decline Despite Market Challenges - The News Heater
Check out these key findings about Annexon Inc (ANNX) - SETE News
Annexon Inc [ANNX] Investment Guide: What You Need to Know - Knox Daily
A year in review: Annexon Inc (ANNX)’s performance in the last year - US Post News
Market Update: Annexon Inc (ANNX) Sees Negative Movement, Closing at 3.52 - The Dwinnex
Analyzing the Impact of Earnings Reports on Annexon Inc Inc. (ANNX) Price Performance - The InvestChronicle
Annexon, Inc. (NASDAQ:ANNX) Short Interest Up 23.7% in January - MarketBeat
Annexon (NASDAQ:ANNX) and Tonix Pharmaceuticals (NASDAQ:TNXP) Head-To-Head Comparison - Defense World
What's Driving These Stocks Higher In After-hours? - RTTNews
Vanguard Group Inc's Strategic Acquisition of Annexon Inc Shares - GuruFocus.com
Annexon stock touches 52-week low at $3.85 amid market challenges - Investing.com Canada
Critical Survey: Day One Biopharmaceuticals (NASDAQ:DAWN) vs. Annexon (NASDAQ:ANNX) - Defense World
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals - MSN
Cantor Fitzgerald Estimates Annexon FY2025 Earnings - Defense World
Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of “Buy” by Brokerages - Defense World
Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Guillain-Barré Syndrome Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Chafic Karam, Hansa Biopharma AB, Annexon - The Globe and Mail
Guillain-Barre Syndrome Market to Reach New Heights in Growth - openPR
Annexon (NASDAQ: ANNX) Issues Press Release Outlining 2025 Outlook - Defense World
Hennion & Walsh Asset Management Inc. Boosts Position in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Short Interest Update - MarketBeat
Barclays PLC Boosts Stake in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Barclays PLC Acquires 120,789 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year - GlobeNewswire
Annexon Advances Three Breakthrough Therapies, Including First Targeted GBS Treatment - StockTitan
JPMorgan Chase & Co. Has $10.10 Million Stake in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Expands Board with Appointment of New Member William Jones - Defense World
Annexon Biosciences Strengthens Board for Strategic Growth - TipRanks
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones - GlobeNewswire
Annexon Strengthens Board with Commercial Veteran BJ Jones Ahead of Late-Stage Drug Launches - StockTitan
ANNXAnnexon, Inc. Latest Stock News & Market Updates - StockTitan
Jane Street Group LLC Sells 39,601 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon: Breakthrough In Guillain-Barré Faces Upcoming FDA Hurdles (NASDAQ:ANNX) - Seeking Alpha
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Annexon (NASDAQ:ANNX) Stock Price Down 4.3%Here's Why - MarketBeat
Franklin Resources Inc. Acquires Shares of 49,406 Annexon, Inc. (NASDAQ:ANNX) - Defense World
Barclays PLC Has $1.05 Million Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Geode Capital Management LLC Grows Stake in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Geode Capital Management LLC - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by State Street Corp - Defense World
Annexon (ANNX) Surges with Promising Phase 3 Results for Guillain-Barré Syndrome Treatment - TipRanks
State Street Corp Has $22.74 Million Stake in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Annexon (NASDAQ:ANNX) Shares Down 3.8%Time to Sell? - MarketBeat
HC Wainwright Reaffirms Buy Rating for Annexon (NASDAQ:ANNX) - Defense World
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Annexon Inc Stock (ANNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Carson William H. | Director |
Dec 02 '24 |
Buy |
5.33 |
3,200 |
17,056 |
25,600 |
| Love Douglas | PRESIDENT AND CEO |
Oct 30 '24 |
Option Exercise |
1.85 |
114,449 |
211,742 |
310,570 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Oct 15 '24 |
Option Exercise |
1.85 |
5,408 |
10,005 |
76,773 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Oct 15 '24 |
Sale |
7.41 |
5,408 |
40,073 |
71,365 |
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):